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Abstract
Background: Women with cervical cancer now have relatively good 5-year survival rates. Better survival rates have
driven the paradigm in cancer care from a medical illness model to a wellness model, which is concerned with the
quality of women’s lives as well as the length of survival. Thus, the assessment of quality of life among cervical
cancer survivors is increasingly paramount for healthcare professionals. The purposes of this review were to
describe existing validated quality of life instruments used in cervical cancer survivors, and to reveal the
implications of quality of life measurement for Chinese cervical cancer survivors.
Methods: A literature search of five electronic databases was conducted using the terms cervical/cervix cancer,
quality of life, survivors, survivorship, measurement, and instruments. Articles published in either English or Chinese
from January 2000 to June 2009 were searched. Only those adopting an established quality of life instrument for
use in cervical cancer survivors were included.
Results: A total of 11 validated multidimensional quality of life instruments were identified from 41 articles. These
instruments could be classified into four categories: generic, cancer-specific, cancer site-specific and cancer
survivor-specific instruments. With internal consistency varying from 0.68-0.99, the test-retest reliability ranged from
0.60-0.95 based on the test of the Pearson coefficient. One or more types of validity supported the construct
validity. Although all these instruments met the minimum requirements of reliability and validity, the original
versions of these instruments were mainly in English.
Conclusion: Selection of an instrument should consider the purpose of investigation, take its psychometric
properties into account, and consider the instrument’s origin and comprehensiveness. As quality of life can be
affected by culture, studies assessing the quality of life of cervical cancer survivors in China or other non-English
speaking countries should choose or develop instruments relevant to their own cultural context. There is a need to
develop a comprehensive quality of life instrument for Chinese cervical cancer survivors across the whole
survivorship, including immediately after diagnosis and for short- (less than 5 years) and long-term (more than
5 years) survivorship.
Introduction
Cervical cancer is one of the most common types of
cancer in developing countries. With nearly 500 000
women developing cervical cancer per year, China’s esti-
mated 131 500 new cases constitute 28.8% of the total
new cases annually worldwide [1]. Due to widespread
screening programs, the majority of cervical cancer
cases are being diagnosed in the earlier stages. Along
with new and advanced medical treatment, women with
cervical cancer have relatively good 5-year survival rates.
The overall 5-year survival rate of all stages of cervical
cancer among Chinese women has been estimated to be
70.93% [2].
Better survival rates have driven the paradigm in the
life-altering burden of cancer care from a medical illness
model to a wellness model concerned with the quality
of women’s lives as well as the length of survival [3].
The current reality of cancer therapies has also led us to
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cancer survivors’ lives [4]. Quality of life (QOL) is one
of the health outcomes that enable healthcare providers
to better address the ongoing concerns of cancer
survivors.
Due to cultural differences, Chinese cancer survivors
may have a different interpretation of QOL. The con-
cept of QOL is defined by Western cancer survivors as
being healthy and independent, reclaiming life, psycho-
logical well-being or social relationships [5]. Chinese
cancer survivors view “normal living”,ag o o dw o r k i n g
life, happiness, material resources and support from
their families as essential indicators of QOL [6,7].
As QOL in cancer survivors varies by treatment, time
since diagnosis and cancer sites [8], there is a need to
review QOL measurement issues with a focus on speci-
fic cancer sites. While Vistad et al. [9] reviewed studies
about the impact of cervical cancer on women’s QOL,
their review revealed little about QOL measurement for
this target population. Although Pearce et al. [10] and
Zebrack & Cella [11] conducted methodological reviews
of QOL measurement in various types of cancer survi-
vors, there is a lack of review articles focusing on QOL
measurement in cervical cancer survivors.
Aims
The purpose of this review was to describe existing vali-
dated multidimensional QOL instruments used in cervi-
cal cancer survivors, and to reveal implications of QOL
measurement for Chinese cervical cancer survivors.
Framework of quality of life
Quality of life is dynamic and changes over time [12].
Traditional models of QOL are a multidimensional con-
struct of health including physical, psychological, social
and spiritual well-being [13]. It has been argued that
this traditional framework predominantly focuses on the
individual-centered paradigm, and ignores contextual
factors that influence QOL [14]. The contextual QOL
model proposed by Ashing-Giwa [14] includes both the
individual and systemic paradigms, and was adopted as
the framework for this review.
Within each level of paradigm, there are four major
domains and a variety of components. The individual
level consists of (1) General Health domain including
components of health status and co-morbidity; (2) Med-
ical Factors domain including components of age at
diagnosis and cancer characteristics; (3) Health Efficacy
domain including components of health practices, utili-
zation, perceived health efficacy and medical adherence;
and (4) Psychological Well-being domain including
components of emotional distress, cognitive function,
and positive psychological feelings [14]. The systemic
level consists of (1) Socio-ecological domain including
components of socio-economic status, life burden, social
support, and role/relationship changes; (2) Cultural
domain including components of spirituality, accultura-
tion, and interconnectedness; (3) Demographic domain
including components of chronological age; and (4)
Healthcare System domain including components of
access to health care and satisfaction with the quality of
health care [14].
Methods
Searching strategies
Articles published in English or in Chinese from January
2000 to June 2009 were searched for the review. Terms
used for searching included cervical cancer, cervix can-
cer, survivors, survivorship, quality of life, measurement,
assessment,a n dinstruments, which were searched in
five computerized databases: CINAHL, Medline, Psy-
cInfo, Scopus, and the Chinese Journal Full-text Data-
base (CJFD). In this review, the term ‘cervical cancer
survivor’ was adapted to mean a person living with cer-
vical cancer immediately after the initial diagnosis [15].
The process of search and selections
Initially, a total of 296 articles were identified from the
literature search of the five databases using the above
key words. Duplications of articles and those articles
that did not meet the selection criteria were removed.
Only 53 articles remained. Twelve of these had used
self-designed instruments and did not report reliability
and validity. As a result, a total of 41 articles were
included. The flowchart of search and selection process
was outlined in figure 1.
Inclusion and exclusion criteria
A checklist was used to select the literature. For inclu-
sion, all of the following criteria had to be fulfilled by
the articles: (1) QOL was one of primary outcome mea-
sures; (2) women with a diagnosis of cervical cancer
constituted the study population; (3) papers were pub-
lished either in English or in Chinese between January
2000 and June 2009 (at time of search). In terms of
exclusion criteria, all qualitative studies, commentaries,
editorials, literature reviews, and conference proceedings
were excluded from this review. As the concept of QOL
is multidimensional (including the physical, psychologi-
cal, social and spiritual well-being dimensions) [13], stu-
dies focusing on a single domain of QOL only were
excluded.
Common types of reliability and validity in QOL
measurement
The basic characteristics of a good QOL instrument
should demonstrate evidence of adequate reliability and
validity [10]. The most common types of reliability
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tency (assessing the homogeneity of the scale) and test-
retest reliability (assessing the stability of the scale) [16];
common types of validity reported by researchers
include content validity (to what degree all items in a
QOL instrument quantitatively represent the actual con-
tent area of the study) and construct validity (how well
items reflect the latent variable in question), which can
be assessed by convergent/divergent validation, known-
group/contrasted-group validation and factor analysis
approaches [17].
The minimum acceptable level of reliability and validity
According to DeVellis [18], the acceptable level of inter-
nal consistency by Cronbach’s alpha should be above
0.7. Fitzpatrick et al. [19] suggested that instruments
examining test-retest reliability within 2-14 days and
achieving a Pearson’s correlation of over 0.7 were con-
sidered to be acceptable. If calculated by the Kappa
coefficient or ICC (Intra-class Correlation Coefficient),
an item total correlation of at least 0.2 is coded as
acceptable [20]. In terms of construct validity, a conver-
gent correlation score above 0.4 is coded as an accepta-
ble standard [21]. By factor analysis, DeVellis [18]
suggested that the eigenvalues of factors greater than
0.5 were considered to be acceptable. With known-group
validity, the scale can differentiate among the groups
[18].
Results
Among the 41 articles identified, 11 validated multidi-
mensional instruments had been administered to assess
QOL among cervical cancer survivors.
Types of multidimensional QOL instruments
After careful review of the characteristics and use of
instruments in these studies, the instruments could be
classified into four categories: generic instruments, can-
cer-specific instruments, cancer site-specific instru-
ments, and survivor-specific instruments.
The generic questionnaires were designed to assess
general aspects of QOL. This category included 4 instru-
ments: the 36-item short form of the Medical Outcome
Study questionnaire (SF-36) [22,23], the World Health
Organization Quality of Life-Brief (WHOQOL-BREF)
[24,25], the Quality of Life Index (QLI) [26], and the
European Quality of Life Scale-5 dimensions (EQ-5D)
[27]. The cancer-specific instruments were designed to
Figure 1 Flowchart of search and selection process.
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gory contained 3 instruments: the Cancer Rehabilitation
Evaluation System-Short Form (CARES-SF) [28], the
European Organization for Research Treatment’sQ u a l -
ity of Life Questionnaire (EORTC QLQ-C30) [29,30],
and the Functional Assessment of Cancer Therapy-Gen-
eral (FACT-G) [31,32]. The cancer site-specific QOL
instruments were developed to measure the QOL of cer-
vical cancer patients. This category consisted of 3 scales:
the EORTC Quality of Life Questionnaire-Cervix-
24items (QLQ-Cx24) [33], the Functional Assessment of
Cancer Therapy-Cervix (FACT-Cx) [34,35], and the
Quality of Life Instruments for Cancer Patients-Cervical
Cancer (QLICP-CE) [36]. The survivor-specific category
included the Cancer Survivors’ Unmet Needs (CaSUN)
scale [37], which was developed to assess QOL among
long-term cancer survivors using a needs-based
approach.
A brief description of each instrument, including cate-
gories, origin of countries and sample items, is shown in
additional file 1. While these instruments varied in
length and emphasis, they shared the common perspec-
tive that QOL is a multidimensional concept including
physical, psychological, social and spiritual well-being,
and environmental conditions.
The paradigms, domains, components and distribution
of items
There was a great variation in the domains and number
of items in these 11 multidimensional QOL instruments.
While these instruments were developed by different
researchers and framed by different QOL models with
combinations of related domains, it was considered ben-
eficial to identify the common shared domains and com-
ponents adopted to assess QOL among cervical cancer
survivors. The item distribution of these 11 multidimen-
sional instruments was tabulated according to Ashing-
Giwa’s contextual QOL model [14] (additional file 2).
Additional file 2 shows that, at the individual level,
items in these QOL instruments mainly covered the
domains of ‘general health’ and ‘psychological health’,
with few covering ‘medical factors’ and ‘health efficacy’.
At the systemic level, these QOL instruments mainly
included items to measure the socio-ecological domain,
i.e. in the components of ‘socio-economic status’, ‘social
support’,a n d‘role/relationship changes’. Very few items
in these instruments covered the ‘cultural domain’ or
the ‘healthcare system’.
The psychometric properties of multidimensional QOL
instruments
Generic QOL instruments
The SF-36 was developed by a medical outcomes health
survey. Broadly, it consisted of 8 dimensions: physical
functioning, role limitations due to physical health pro-
blems, bodily pain, general mental health covering psy-
chological distress and well-being, role limitations due
to emotional problems, social functioning, vitality, and
general health perceptions [38]. The internal consistency
for the overall scale was 0.95 [38]. The test-retest corre-
l a t i o n sw e r em o r et h a n0 . 8i nt h ep h y s i c a lf u n c t i o na n d
general health perceptions domains [39]. Correlations of
convergent validity between the SF-36 and the WHO-
QOL-BREF were: the physical component summary of
SF-36 with the physical domains of WHOQOL-BREF
was 0.48; and the mental component summary of SF-36
with the whole WHOQOL-BREF scale ranged from
0.6-0.75 [40].
The WHOQOL-BREF was a brief version of the QOL
instrument developed from the WHOQOL-100. It com-
prised 26 items covering physical, psychological and
social health, and environmental domains as well as
overall QOL and health [41]. The internal consistency
ranged from 0.75-0.86 [40]. The test-retest reliability
correlation ranged from 0.76-0.8 in an interval of 2-4
weeks [42]. The content validity was assessed by asses-
sing the item-domain correlations (0.53-0.78) and the
inter-domain correlation (0.51-0.64) [42]. By convergent
validation with SF-36, the mental health domain had a
high correlation of 0.75, and the lowest correlation in
the physical functioning domain was 0.51 [40]. Factorial
validity revealed 4 domains, and known-group validation
differentiated the study population between sick and
well individuals [43].
The QLI was designed to measure both the satisfac-
tion and importance of various aspects of life, including
the four domains of health and functioning, psychologi-
cal/spiritual, social and economic, and family [44]. This
scale consisted of 66 items to rate for satisfaction and
importance of QOL. The internal consistency alpha ran-
ged from 0.73-0.99 [44]. The test-retest reliability was
tested in a 2-week interval, and ranged from 0.68-0.79
[45]. Content validity was assessed by using the Content
Validity Index, with an acceptable rating level [46]. By
convergent validation with the Life Satisfaction Scale,
the correlation ranged from 0.61-0.93; factor analysis
derived 4 domains [45].
The EQ-5D consisted of 6 items covering 5 dimen-
sions of health: mobility, self-care, usual activities, pain/
discomfort, and anxiety/depression, plus a global ques-
tion to rate general health state [47]. The test-retest
reliability was tested over a 1-week interval and reported
as 0.86 for group level coefficients averaged over health
states [48]. The content validity was verified by the
research panel. Using convergent validation with the
Hospital Anxiety and Depression Scale, the correlation
was reported respectively as 0.44 (Anxiety scale) and
0.51 (Depression scale) [49].
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The CARES-SF contained 59 items, covering physical,
psychological, medical interaction, marital, and sexual
domains [50]. In Schag et al.’s validation study, the relia-
bility of internal consistency had an estimated alpha ran-
ging from 0.61-0.85, and the test-retest correlation was
0.92 with a 1-month interval. The content validity of
this scale was assessed by experts. Using convergent
validation with the CARES, the correlation ranged from
0.67-0.85. Factorial validity revealed 6 domains, and
known-group validation was able to distinguish between
normative and rehabilitation individuals [50].
The EORTC QLQ-C30 consisted of 30 items and
included 5 functional domain scales, such as physical, role,
emotional and social functions, along with disease-specific
symptoms, a financial impact domain, and two items
related to global health status and QOL [51]. The internal
consistency with an estimated alpha ranged from 0.74-0.86
[51]. The test-retest correlation over a 4-day interval ran-
ged from 0.82-0.91 [52]. By convergent validation with the
CARES, the correlation was respectively reported as 0.46
(Social domain), 0.56 (Psychological domain), 0.69 (Pain
symptoms), and 0.71 (Physical domain) [53].
The FACT-G included 27 items and covered 4 pri-
mary QOL domains: physical, emotional, social and
functional well-being [54]. Cella et al.’s validation report
shows an internal consistency alpha of 0.89 for the total
instrument, and a test-retest correlation ranging from
0.82-0.92 over a 3- to 7-day interval. The convergent
validation with the Functional Living Index-Cancer
Scale was 0.79. By using known-group validation, the
FACT-G can significantly differentiate between patients
at different stages of disease [54].
Cancer site-specific QOL instruments
The EORTC QLQ-Cx24 was developed to measure cer-
vical cancer and its treatment-related issues. It covers
the symptom experience, body image, and sexual/vaginal
functioning subscales. The internal consistency of this
scale ranged from 0.72-0.87 [55]. By convergent valida-
tion with the EORTC QLQ-C30, the correlation ranged
from 0.4-0.48. The negative correlations of the body
image subscale of QLQ-Cx24 with the emotional func-
tion and the global health/QOL of QLQ-C30 were
minus 0.43 and 0.41. Known-group validation could dis-
tinguish subgroups of patients based on their clinical
status [55].
The FACT-Cx consisted of 42 items: 27 items from
the FACT-G plus 15 additional items to measure speci-
fic cervical cancer concerns. It was translated into 27
languages for use among a group of cross-cultural can-
cer patients [16]. The internal consistency alpha for
each domain ranged from 0.69-0.89 [56]. Known-group
validation could distinguish subgroups of patients with
different types of treatment [56].
The QLICP-CE consisted of 40 items covering
5 domains of QOL: physical function, psychological
function, social function, common symptoms and side-
effects, and specific concerns of cervical cancer. Zhang
et al. [36] reported that the internal consistency alpha
for the overall scale was 0.68 and the test-retest reliabil-
i t yo v e ra3 - d a yi n t e r v a l0 . 9 5 .T h ec o n t e n tv a l i d i t yw a s
verified by experts. The factor loading of all items that
remained in the scale was at least 0.6 by factor analysis
[36].
QOL instruments for long-term cancer survivors
The CaSUN was developed using a needs-based
approach to assess QOL among cancer survivors. This
instrument consisted of 35 items covering 5 domains:
information and medical issues, QOL, emotional and
relationship issues, life perspective, and positive change
issues [37]. The internal consistency had an estimated
alpha of 0.96. Based on a 3-week interval, the test-retest
correlation by an estimation of the Kappa coefficient
was 0.13 [37]. The content validity was verified by the
research panel and feedback from respondents. By con-
vergent validation with the Hospital Anxiety and
Depression Scale, the correlation was respectively
reported as 0.4 (Anxiety subscale), and 0.34 (Depression
subscale) [37].
Summaries of psychometric properties
Additional file 3 also shows the psychometric properties
of reliability and validity. The internal consistency of
these 11 established multidimensional QOL instruments
met the acceptable standards (0.68-0.99). In terms of the
test-retest correlation, the average item-item correlation
of CaSUN by Kappa coefficient was 0.13, below the
acceptable level of correlation. Although the test-retest
reliability of QLICP-CE was 0.95 by Pearson’s coefficient
test, the retest interval was a mere 2-3 days. Chawalow
& Adesina [57] indicated that high test-retest correlation
indices obtained over a short period (<1 week) may sim-
ply be reflected memory rather than actual stability of
participants’ perceptions. Consequently, higher test-retest
correlations do not actually reflect the stability of an
instrument if the retest interval is short.
For the establishment of validity, all these instruments
had one or more types of construct validity reported.
Most had conducted convergent validity which met
acceptable standards. Other reported approaches of
validity, such as factor analysis and known-group valida-
tion, were also considered acceptable.
Discussion
There were 11 validated multidimensional QOL instru-
ments, which could be classified into four categories:
generic, cancer-specific, cancer site-specific and cancer
survivor-specific instruments. All these instruments met
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with the internal consistency of reliability varying from
0.68-0.99 and the test-retest reliability ranging from 0.6-
0.95 based on the test of the Pearson coefficient. One or
more types of validity supported the construct validity.
General QOL measurement issues in cervical cancer
survivors
The original versions of these 11 QOL instruments were
mainly developed in Europe and North America, there-
fore how to select those that would be most appropriate
for Chinese cervical cancer survivors requires careful
consideration by researchers.
Among the generic scales, the WHOQOL-BREF was
the most often-used scale among QOL studies in cervi-
cal cancer survivors. Some studies chose this scale
because it had been translated and validated in their lan-
guage [24,25]. Hence, these studies chose generic scales
based on practical issues. One study chose the generic
scale of QLI because there was a control group from the
general population [26]. Generic scales were designed
and validated in the general population. If the study
objectives aimed at making a comparison of QOL
between cancer survivors and the general population,
choosing one of the generic scales would be suitable.
However, while these generic instruments may be useful
for making comparisons of QOL between cervical can-
cer survivors and the general population, they may not
be sensitive enough to detect the impact of cancer and
cancer treatment on QOL among cervical cancer
survivors.
The majority of QOL studies in cervical cancer survi-
vors chose cancer-specific scales. EORTC QLQ-C30 and
FACT-G were the most frequently used. It is possible
that cancer-specific scales are more responsive to
changes than their generic counterparts, because cancer-
specific instruments cover items in addressing the
effects of cancer and related treatment on QOL. In con-
sequence, it would be logical to speculate that cancer-
specific scales would be more appropriate than generic
scales in assessing QOL among cancer survivors. How-
ever, this speculation is only partially substantiated. Due
to a failure to identify concerns specific to cervical can-
cer, these instruments may not be the most suitable for
assessing QOL among cervical cancer survivors.
Cancer site-specific instruments may achieve greater
specificity and sensitivity than either generic or cancer-
specific scales, as site-specific scales cover general can-
cer-specific issues and address specific concerns related
to cervical cancer. There were three site-specific instru-
m e n t su s e db ys t u d i e si no u rr e v i e w :E O R T CQ L Q -
Cx24, FACT-Cx and QLICP-CE. It may be speculated
that these cancer site-specific scales are the most suita-
ble choice for QOL studies in cervical cancer survivors.
Yet these scales are more concerned with the immediate
effects of cancer and acute cancer treatment, so that
they are not appropriate for cervical cancer survivors
due to the lack of items covering the long-term sequelae
of cervical cancer, such as loss of fertility, sexual dys-
function, fear of recurrence, and body image disturbance
[58].
In addition, cancer survivors reported positive changes
in life outlook, self-growth, precious life, and an appre-
ciation of their relationships with others [37]. All 11
QOL instruments used in cervical cancer survivors paid
less attention to the positive outcome of the cancer sur-
vivorship experience. In more recent years, the trend of
QOL instrument production has continued to emerge
for cancer survivors, particularly for long-term (more
than 5 years) cancer survivors with an emphasis on
positive outcomes [10], such as the Quality of Life Scale
for Adult Cancer Survivors (QLACS) by Avis et al. [59]
and the Impact of Cancer (IOC) by Zebrack et al. [60].
However, these long-term cancer survivor-specific
instruments have not been applied to the population of
cervical cancer survivors.
According to Ashing-Giwa’s contextual model [14],
socio-ecological, cultural and healthcare system-related
factors are essential components in the systemic level of
QOL among cancer survivors. Additional file 2 shows
the paradigm, domains, components and item distribu-
tion. These 11 multidimensional QOL instruments did
not adequately incorporate the contextual milieu. In
other words, there were few items that captured the
contextual domain of QOL, such as socio-ecological and
cultural issues. Even if the instrument of WHOQOL-
BREF had an environmental domain, this scale covered
too few items to measure the environmental domain of
QOL adequately. Therefore, neither of these instruments
was comprehensive enough to address or cover all QOL
issues among cervical cancer survivors.
Specific issues of QOL measurement in Chinese cervical
cancer survivors
Although the instruments of EORTC QLQ-C30, FACT-
G, and FACT-Cx had been applied to Chinese cervical
cancer survivors, few studies calculated its reliability and
validity when applied to Chinese women. Only one
study by Wan et al. [61] established and reported
FACT-G as having good reliability and validity among
different types of Chinese cancer patients.
Recently, Zhang and colleagues developed the scale of
QLICP-CE and validated it among a group of Chinese
women with cervical cancer [36]. The domains and
items included in the scale of QLICP-CE were mainly
based on the instruments of EORTC QLQ-C30 and
FACT-Cx. The QLICP-CE emphasized the aspects of
women’s appetite and sleep, as within Chinese culture
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daily life [62]. Due to Chinese communities viewing sex
as a taboo topic, the QLICP-CE consists of just one
item to measure the issues of sexual health. As sexuality
is one of the essential components of QOL [63], this
scale failed to address an important aspect of QOL for
Chinese cervical cancer survivors.
Furthermore, culture is a major determinant of QOL,
as perceptions of QOL are embedded in cultural beliefs
about what constitutes normality and health [64]. At the
individual level, the components of health practices,
health utilization and perceived health practice should
be measured in a culturally sensitive manner, because in
Chinese culture the beliefs of Taoism (human beings
should live in harmony with nature, that is, with ‘Tao’
as the way of life) and traditional Chinese medicine
(TCM) (expanded from Taoism, it views health as har-
mony between vital energy - known as Qi - within and
between the body and its environment) are dominate
the views of health and health utilization [62,65]. These
beliefs are different from those of Western people,
therefore perceptions of QOL logically also differ
between China and the West. Due to differences of
social backgrounds and healthcare systems, at the sys-
temic level the components of socio-economic status,
access to and satisfaction with health care, and role and
relationship changes should be particularly emphasized.
Since the family relationship and kinship play very
important roles in daily life in Chinese communities
[62], roles and relationship changes due to cancer and
treatment greatly influence Chinese women’s QOL.
Limitations of the review
In searching for literature, the 5 electronic databases
used provided a comprehensive coverage of key English
and Chinese medical, nursing and health-affiliated jour-
nals. However, the titles and abstracts were screened
only by the first author. In order to compensate for this
limitation, all articles were screened using a checklist
based on clear inclusion and exclusion criteria. Addi-
tionally, all eligible articles were agreed upon by the
research team. Other limitations include that the assess-
ment of the psychometric properties of QOL instru-
ments was limited to the reliability and validity. This
review failed to assess other instrument properties, such
as cross-cultural acceptability, responsiveness, and
acceptability, because those properties were seldom
reported by the instrument developers.
Conclusion
According to this review, a total of 11 validated multidi-
mensional instruments have been used to assess QOL
among cervical cancer survivors. Almost all these QOL
instruments were originally developed in North America
or Europe. Due to cultural differences between these
regions and China, further research needs to explore cul-
turally specific issues in detail, such as what QOL
domains are known to be important for Chinese women.
Regarding the issue of instrument selection, choosing an
instrument for Chinese cervical cancer survivors should
first take consideration of the QOL instruments’ psycho-
metric properties. Based on this review, all 11 instruments
met the minimum requirements of reliability and validity.
Secondly, instrument selection should be based on the
purpose of investigation. From the previous discussion, if a
study aims to compare the QOL of Chinese cervical can-
cer survivors with that of the general Chinese female
population, the WHOQOL-BREF could be one of the
potential instruments. By contrast, if the purpose of the
study is to investigate QOL among survivors of different
types of cancer including cervical cancer, QLACS, CaSUN
and IOC should be translated and applied to Chinese cer-
vical cancer survivors. Lastly, if the aim is simply to inves-
tigate QOL among short-term cervical cancer survivors,
the QLICP-CE would be a potential choice.
Finally, instrument selection for Chinese cervical can-
cer survivors also needs to consider the comprehensive-
ness of the instruments. This issue could be addressed
by incorporating different types of QOL instruments
based on the purpose of investigation. However, choos-
ing multiple QOL instruments, there is a high possibility
that more time will be required of respondents. Conse-
quently, further research is needed to develop an instru-
ment tailored to assessing QOL for Chinese cervical
cancer survivors across the whole survivorship, includ-
ing immediately after diagnosis, in the short term (less
than 5 years), and in the long term (more than 5 years).
Additional file 1: Categories of the established multidimensional
QOL instruments adopted by studies in cervical cancer survivors.
Additional file 2: The paradigm, domains, components and
distribution of items across 11 multidimensional QOL instruments.
Additional file 3: The psychometric properties of the 11 established
multidimensional QOL instruments.
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